Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients
Launched by AUSTRIAN BREAST & COLORECTAL CANCER STUDY GROUP · Mar 31, 2006
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients with bioptically verified breast cancer
- • Estrogen receptor-negative status
- • Age: \< 70 years
- • WHO Performance Status \< 2
- • Laboratory parameters
- • 1. hematopoiesis: \> 3500/mm3 leukocytes, \> 100,000/mm3 thrombocytes
- • 2. renal function: creatinin \< 1.5mg%
- • 3. hepatic function: GOT max. 2.5 x UNL
- • 4. bilirubin: \< 2.0 mg %
- • 5. metabolic parameters: Na, Ca, K in normal range
- • \</= 4 weeks interval since surgery
- • Informed consent
- Exclusion Criteria:
- • Patients with locally inoperable cancer, M1
- • Other preoperative tumor-specific radiotherapy, chemotherapy or endocrine treatment
- • Pregnancy or lactation
- • General contraindication against cytostatic treatment
- • T4 cancer; inflammatory disease, simultaneous or sequential bilateral breast cancer
- • Lacking compliance or understanding of disease
- • Serious concomitant disease
- • Second carcinoma or status post second carcinoma (except for treated squamous cell carcinoma of the skin or cervical carcinoma in situ)
About Austrian Breast & Colorectal Cancer Study Group
The Austrian Breast & Colorectal Cancer Study Group (ABCSG) is a leading clinical research organization dedicated to advancing the understanding and treatment of breast and colorectal cancers. Comprising a multidisciplinary team of oncologists, researchers, and healthcare professionals, ABCSG focuses on designing and conducting high-quality clinical trials that aim to improve patient outcomes through innovative therapies and evidence-based practices. With a commitment to collaboration and scientific rigor, the group plays a pivotal role in contributing to the global body of knowledge in oncology, fostering advancements in cancer care and enhancing the quality of life for patients affected by these diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Raimund Jakesz, MD
Principal Investigator
Austrian Breast & Colorectal Cancer Study Group
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials